作者: Maarten F. Schim van der Loeff , Alex Vorsters , Elske Marra , Pierre Van Damme , Arjan Hogewoning
DOI: 10.1080/21645515.2019.1602432
关键词:
摘要: Prophylactic vaccines are efficacious in preventing Human Papillomavirus (HPV) infection and subsequent cervical intraepithelial neoplasia (CIN), cancer, other anogenital cancers, warts. Female sex workers (SW) at increased risk of acquiring sexually transmitted infections, including HPV. There several reasons to offer HPV vaccination SW: they high for often unvaccinated, the immunogenicity vaccine is also excellent previously exposed women. Furthermore, women with disease caused by may still benefit from vaccination. The efficacy vaccinating mid-adult (26-44 years old) against persistent CIN2+ good. Although an SW have been infected or HPV, she not all vaccine-included hrHPV types. Vaccination induces mucosal immunity via production neutralizing antibodies on surface female genital tract, thus potential transmission clients. Nevertheless, some considerations argue offering SWs. Current only prophylactic as such, do affect current infections. Women who cleared so again need Fewer might be naive HPV-types than currently thought. has probably no effect latent Vaccinating sometime after sexual debut could too late, infections already occurred. Taken together, data suggest that health benefits, community, but sufficient evidence lacking. In certain cases, recommended. Evidence-based, public decisions concerning challenging facilitated more research this high-risk group.